MEGACE ES SUMMARY
Megace® ES (megestrol acetate) oral suspension contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone.
Megace® ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).
Published Studies Related to Megace ES (Megestrol)
[Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss]. [2011.07.23]
BACKGROUND AND OBJECTIVE: Weight loss in patients with severe chronic obstructive pulmonary disease (COPD) is a prognostic bad factor. The objective of this study is to analyze the effectively of megestrol acetate (MA) to increase appetite of these patients... CONCLUSIONS: MA safely increases the body weight and the appetite in severe COPD patients with weight loss. MA improves blood gases and nutritional parameters and the sense of wellbeing, but it does not improve the respiratory muscular function or exercise tolerance. Copyright (c) 2010 Elsevier Espana, S.L. All rights reserved.
Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17beta-estradiol (NOMAC/E2): a double-blind, randomized study. [2011.06]
BACKGROUND Nomegestrol acetate/17beta-estradiol (NOMAC/E(2)) is a new monophasic oral contraceptive combining NOMAC (2.5 mg), a highly selective progesterone-derived progestogen, with E(2) (1.5 mg), which is structurally identical to endogenous estrogen... CONCLUSIONS The 24-day NOMAC/E(2) regimen was associated with greater inhibition of follicular growth and shorter duration of withdrawal bleeding than the 21-day regimen, suggesting the shorter pill-free interval results in a greater margin of contraceptive efficacy and tolerability, and fewer withdrawal symptoms.
Antiemetic activity of megestrol acetate in patients receiving chemotherapy. [2011.05]
PURPOSE: Several trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature. Our objective was to evaluate the antiemetic ability of megestrol acetate in patients receiving chemotherapy... CONCLUSION: Megestrol acetate was shown to be an effective antiemetic agent. Megestrol acetate might be a new antiemetic option for chemotherapy.
Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17beta-oestradiol: a double-blind, randomised, dose-finding pilot study. [2011.04]
OBJECTIVE: To explore the optimal dose of the progestogen, nomegestrol acetate (NOMAC), required in a monophasic oral contraceptive, in combination with 1.5 mg 17beta-oestradiol (E(2)), to inhibit ovulation... CONCLUSION: The dose of 2.5 mg NOMAC was confirmed to be optimal to inhibit both ovulation and follicular maturation. The antigonadotropic effect of 2.5 mg NOMAC was reinforced when combined with 1.5 mg E(2).
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. [2011.03]
Use of oral contraceptives (OC) that combine a progestogen with synthetic ethinyl estradiol (EE) is associated with increased risk of venous thromboembolism. NOMAC/E2 is a new monophasic OC that combines nomegestrol acetate (NOMAC), a highly selective progestogen, with 17beta-estradiol (E2)...
Clinical Trials Related to Megace ES (Megestrol)
Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers [Not yet recruiting]
Phase I study of Megace F will be conducted to investigate pharmacokinetics and safety
compared to Megace OS.
Phase I study divided into 3 parts written as belows.
Part 1 Megace F in fasting volunteers vs Megace F in fed volunteers Part 2 Megace F vs
Megace OS in fed volunteers Part 3 Megace F vs Megace OS in fasting volunteers
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite [Recruiting]
This randomized phase II trial studies the safety and efficacy of megestrol acetate given
with or without mirtazapine in treating cancer patients with weight loss and loss of
appetite. To date, no pharmacologic interventions have been approved by FDA to treat cancer
anorexia-cachexia syndrome (CACS). Megestrol acetate has been shown to increase appetite in
cancer patients. Adding mirtazapine may provide a much more effective treatment and help
improve quality of life.
Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy [Recruiting]
RATIONALE: Megestrol acetate may help improve appetite and lessen weight loss caused by
cancer. PURPOSE: This clinical trial studies megestrol acetate in treating weight loss or
anorexia in young patients with malignancies who are undergoing radiation therapy and/or
Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition [Recruiting]
The purpose of this study is to evaluate pharmacokinetics of Daewon DW-ES(B) 625mg/5ml and
Megace 800mg/20ml in healthy male volunteers under fasting and fed condition.
Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia [Recruiting]
RATIONALE: Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using
megestrol may fight endometrial cancer by blocking the use of estrogen by the abnormal
PURPOSE: This randomized phase II trial is studying how well megestrol works in treating
patients with endometrial neoplasia or endometrial hyperplasia.
Reports of Suspected Megace ES (Megestrol) Side Effects
Unresponsive TO Stimuli (3),
Mental Status Changes (2),
Stevens-Johnson Syndrome (2),
Drug Ineffective (1),
Infection in AN Immunocompromised Host (1),
Myocardial Infarction (1),
Immunodeficiency (1), more >>